May 2026's Top Stocks That Could Be Trading Below Estimated Fair Value

The United States market has experienced a notable uptick, rising 1.1% over the last week and achieving a 29% increase over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of robust growth, identifying stocks that are potentially trading below their estimated fair value can offer investors opportunities to capitalize on undervalued assets with promising prospects.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Upstart Holdings (UPST) $28.56 $56.20 49.2% Tenable Holdings (TENB) $25.45 $48.32 47.3% Super Group (SGHC) (SGHC) $13.51 $26.84 49.7% Rayonier (RYN) $20.36 $40.08 49.2% Live Oak Bancshares (LOB) $37.28 $74.21 49.8% Kingstone Companies (KINS) $15.92 $31.31 49.1% Gilead Sciences (GILD) $134.36 $268.61 50% FB Financial (FBK) $52.68 $101.61 48.2% Coastal Financial (CCB) $69.66 $134.79 48.3% AbbVie (ABBV) $215.70 $420.47 48.7%

Click here to see the full list of 145 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

Gilead Sciences

Overview: Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs globally, with a market cap of approximately $166.82 billion.

Operations: The company's revenue from the discovery, development, and commercialization of innovative medicines is $29.74 billion.

Estimated Discount To Fair Value: 50%

Gilead Sciences appears undervalued based on cash flows, trading at US$134.36, significantly below its estimated future cash flow value of US$268.61. Despite high debt levels, the company's earnings are expected to grow significantly at 21.1% annually over the next three years, outpacing the US market average. Its recent fixed-income offerings and strategic collaborations further bolster its financial position and potential for sustained profitability amidst slower revenue growth compared to market averages.

The growth report we've compiled suggests that Gilead Sciences' future prospects could be on the up. Click here to discover the nuances of Gilead Sciences with our detailed financial health report.GILD Discounted Cash Flow as at May 2026

Mobileye Global

Overview: Mobileye Global Inc. develops and deploys advanced driver assistance systems and autonomous driving technologies worldwide, with a market cap of $8.57 billion.

Operations: The company generates revenue of $1.98 billion from its advanced driver assistance systems and autonomous driving technologies across various regions, including the United States, Europe, and China.

Story Continues

Estimated Discount To Fair Value: 37.7%

Mobileye Global is trading at US$10.18, significantly below its estimated future cash flow value of US$16.35, suggesting it may be undervalued based on cash flows. Despite a substantial goodwill impairment impacting recent earnings, the company has raised its 2026 revenue guidance due to strong demand and announced a US$250 million share buyback program funded by existing cash and future flows. Expected profitability within three years further supports its potential for long-term growth.

Insights from our recent growth report point to a promising forecast for Mobileye Global's business outlook. Take a closer look at Mobileye Global's balance sheet health here in our report.MBLY Discounted Cash Flow as at May 2026

Flowserve

Overview: Flowserve Corporation designs, manufactures, distributes, and services industrial flow management equipment across various regions including the United States, Canada, Mexico, Europe, the Middle East, Africa, and the Asia Pacific with a market cap of approximately $8.90 billion.

Operations: Flowserve's revenue is primarily generated from its Flow Control Division, contributing $1.47 billion, and its Pump Division, which brings in $3.20 billion.

Estimated Discount To Fair Value: 11.9%

Flowserve is trading at US$69.61, below its estimated future cash flow value of US$79, indicating it might be undervalued based on cash flows. Despite slower revenue growth forecasts compared to the market, its earnings are expected to grow significantly faster than the US market average. Recent financial strategies include issuing US$500 million in senior notes to support potential acquisitions and corporate initiatives, highlighting a focus on strategic growth and capital management.

In light of our recent growth report, it seems possible that Flowserve's financial performance will exceed current levels. Navigate through the intricacies of Flowserve with our comprehensive financial health report here.FLS Discounted Cash Flow as at May 2026

Next Steps

Delve into our full catalog of 145 Undervalued US Stocks Based On Cash Flows here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Curious About Other Options?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GILDMBLY and FLS.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments